TFFP Stock Price, TFF Pharmaceuticals Inc Quote, Chart

Market Summary

USD2.160.00

Delayed

0.00%

TFFP Stock Price

View Fullscreen

TFFP RSI Chart

TFFP Valuation

Market Cap

6.7M

Price/Earnings (Trailing)

-0.34

Price/Sales (Trailing)

7.56

Price/Free Cashflow

-0.45

TFFP Price/Sales (Trailing)

TFFP Profitability

Return on Equity

-375.67%

Return on Assets

-216.92%

Free Cashflow Yield

-222.25%

TFFP Fundamentals

TFFP Revenue

Revenue (TTM)

885.7K

Rev. Growth (Yr)

295.25%

Rev. Growth (Qtr)

77.8%

TFFP Earnings

Earnings (TTM)

-19.9M

Earnings Growth (Yr)

18.67%

Earnings Growth (Qtr)

-20.43%

Breaking Down TFFP Revenue

Last 7 days

10.8%

Last 30 days

-33.3%

Last 90 days

-68.9%

Trailing 12 Months

-86.5%

How does TFFP drawdown profile look like?

TFFP Financial Health

Current Ratio

1.26

TFFP Investor Care

Shares Dilution (1Y)

114.00%

Diluted EPS (TTM)

-9.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	885.7K	0	0	0
2023	479.8K	785.1K	932.3K	733.9K
2022	131.3K	157.4K	195.0K	495.8K
2021	0	0	0	88.2K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of TFF Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 16, 2023	carlson capital l p	sold	-391	0.3916	-1,000	-
Aug 15, 2023	rocamboli stephen	bought	5,000	0.25	20,000	-
Aug 15, 2023	coleman kirk allen	bought	5,000	0.25	20,000	chief financial officer
Aug 15, 2023	mills robert s	bought	10,000	0.25	40,000	-
Aug 15, 2023	mikhak zamaneh	bought	30,000	0.25	120,000	chief medical officer
Aug 15, 2023	carlson capital l p	sold	-94,041	0.4374	-215,000	-
Aug 15, 2023	roberts brandi	bought	5,000	0.25	20,000	-
Aug 15, 2023	weisman harlan f	bought	150,000	0.25	600,000	president and ceo
Mar 10, 2023	rocamboli stephen	bought	10,432	0.8025	13,000	-
Mar 10, 2023	weisman harlan f	bought	131,835	0.8789	150,000	president and ceo

Which funds bought or sold TFFP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	-32.00	193	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-61.96	-435	211	-%
May 15, 2024	Gen-Wealth Partners Inc	new	-	604	604	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-63.41	-6,599	3,032	-%
May 15, 2024	Royal Bank of Canada	added	57.61	1,000	3,000	-%
May 14, 2024	AIGH Capital Management LLC	sold off	-100	-206,964	-	-%
May 14, 2024	DRW Securities, LLC	unchanged	-	-39,200	241,600	0.01%
May 14, 2024	CARLSON CAPITAL L P	unchanged	-	-190,081	1,171,520	0.10%
May 13, 2024	UBS Group AG	reduced	-37.84	-5,921	6,807	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	10.32	-3,002	107,375	-%

Are Funds Buying or Selling TFFP?

Are funds buying TFFP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TFFP

No. of Funds

Unveiling TFF Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 08, 2024	carlson capital l p	9.12%	217,960	SC 13G/A
May 08, 2024	intracoastal capital, llc	4.99%	155,589	SC 13G
Feb 14, 2024	lytton laurence w	0.1%	11,900	SC 13G/A
Feb 14, 2023	lung therapeutics, inc.	2.1%	773,000	SC 13G/A
Feb 13, 2023	lytton laurence w	8.4%	3,125,722	SC 13G/A
Feb 09, 2023	carlson capital l p	5.1%	1,842,000	SC 13G/A
Nov 28, 2022	carlson capital l p	6.2%	2,194,000	SC 13G
Nov 23, 2022	lytton laurence w	8.8%	3,137,641	SC 13G
Feb 14, 2022	lung therapeutics, inc.	8.81%	2,235,000	SC 13G/A
Feb 14, 2022	corriente advisors, llc	0.0%	0	SC 13G/A

Recent SEC filings of TFF Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	424B5	Prospectus Filed
May 17, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 08, 2024	SC 13G	Major Ownership Report
May 08, 2024	SC 13G/A	Major Ownership Report
May 02, 2024	8-K	Current Report
May 01, 2024	424B4	Prospectus Filed
Apr 29, 2024	EFFECT	EFFECT
Apr 29, 2024	EFFECT	EFFECT

Peers (Alternatives to TFF Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

TFF Pharmaceuticals Inc News

Latest updates

TFF Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	77.8%	203	114	235	333	51.00	313	88.00	28.00	67.00	12.00	50.00	2.00	24.00
Operating Expenses	9.3%	5,994	5,483	4,655	5,352	7,138	7,694	7,368	8,780	8,451	10,108	8,728	5,113	7,926
S&GA Expenses	-100.0%	-	2,509	2,269	2,670	3,119	3,560	3,342	3,678	3,213	3,188	2,388	2,351	2,647
R&D Expenses	19.6%	3,556	2,974	2,387	2,682	4,019	4,121	4,026	5,102	5,262	6,920	6,340	2,762	5,278
Interest Expenses	-	-	-	-	36.00	35.00	8.00	6.00	6.00	7.00	10.00	12.00	14.00	15.00
Net Income	-20.4%	-5,735	-4,762	-4,409	-5,020	-7,051	-7,373	-7,274	-8,746	-8,376	-10,049	-8,678	-4,655	-7,654
Net Income Margin	22.3%	-22.50*	-28.95*	-25.59*	-34.03*	-63.45*	-64.08*	-176.63*	-227.72*	-241.92*	-352.07*	-	-	-
Free Cashflow	24.4%	-3,190	-4,221	-3,013	-4,599	-4,506	-7,841	-8,116	-5,509	-7,383	-11,010	-7,333	-6,014	-6,067

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4	2019Q3	2018Q4
Assets	-23.6%	9.00	12.00	15.00	14.00	18.00	24.00	20.00	28.00	34.00	41.00	49.00	57.00	61.00	39.00	43.00	29.00	11.00	10.00
Current Assets	-35.9%	5.00	8.00	11.00	9.00	14.00	19.00	17.00	25.00	32.00	39.00	47.00	55.00	60.00	38.00	42.00	29.00	11.00	10.00
Cash Equivalents	-41.4%	3.00	5.00	10.00	8.00	12.00	17.00	13.00	21.00	26.00	34.00	45.00	52.00	58.00	35.00	42.00	28.00	11.00	10.00
Net PPE	-6.0%	2.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	-	-	-
Liabilities	57.8%	4.00	2.00	1.00	1.00	2.00	1.00	2.00	4.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	1.00
Current Liabilities	59.4%	4.00	2.00	1.00	1.00	2.00	1.00	2.00	4.00	-	2.00	-	-	-	1.00	2.00	0.00	-	1.00
Shareholder's Equity	-44.6%	5.00	10.00	14.00	12.00	17.00	23.00	18.00	24.00	32.00	39.00	48.00	56.00	60.00	37.00	42.00	28.00	-	-
Retained Earnings	-4.9%	-124	-118	-113	-109	-104	-97.09	-89.72	-82.44	-73.69	-65.32	-55.27	-46.59	-41.93	-34.28	-28.38	-15.71	-11.05	-3.84
Additional Paid-In Capital	1.2%	130	128	127	122	121	120	108	106	105	104	103	102	102	72.00	70.00	43.00	0.00	1.00
Shares Outstanding	6.3%	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-
Float	-	-	-	-	17.00	-	-	-	139	-	-	-	229	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	24.7%	-3,144	-4,175	-3,000	-4,458	-4,365	-7,700	-7,339	-5,014	-7,246	-10,883	-7,191	-5,890	-5,591	-6,232	-4,255	-3,774	-2,352	-4,306	-3,071	-1,722	-2,115
Share Based Compensation	7.7%	627	582	766	826	752	923	956	1,195	1,178	921	857	741	1,030	920	546	295	426	211	-229	486	121
Cashflow From Investing	100.0%	-	-46.39	-12.65	-	-	-141	-777	-495	-137	-126	-141	-124	-476	-	-	-	-	-	-	-	-
Cashflow From Financing	158831.0%	901	567*	5,090	-59.23	-17.92	11,336	431	-	-	-	-	26.00	28,859	714	-	-	-	21,851	-10.17	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TFFP Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 203,273	$ 51,429
Operating expenses:
Research and development	3,555,862	4,018,659
General and administrative	2,438,304	3,119,216
Total operating expenses	5,994,166	7,137,875
Loss from operations	(5,790,893)	(7,086,446)
Other income:
Interest income, net	55,749	35,079
Total other income	55,749	35,079
Net loss	$ (5,735,144)	$ (7,051,367)
Net loss per share, basic (in Dollars per share)	$ (2.4)	$ (4.87)
Weighted average common shares outstanding, basic (in Shares)	2,387,906	1,447,723
Other comprehensive loss:
Foreign currency translation adjustments	$ (55,595)	$ (18,669)
Comprehensive loss	$ (5,790,739)	$ (7,070,036)

TFFP Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,211,930	$ 5,478,113
Research and development tax incentive receivable	287,597	433,852
Prepaid assets and other current assets	1,362,989	1,678,353
Total current assets	4,862,516	7,590,318
Operating lease right-of-use asset, net	99,431	119,529
Property and equipment, net	1,879,696	1,999,781
Note receivable - Augmenta	2,337,219	2,310,000
Other assets	7,688	7,688
Total assets	9,186,550	12,027,316
Current liabilities:
Accounts payable	1,663,544	958,442
Accrued liabilities	1,983,426	1,285,586
Deferred research grant revenue	140,000	101,000
Current portion of operating lease liability	84,300	83,512
Total current liabilities	3,871,270	2,428,540
Operating lease liability, net of current portion	10,856	31,742
Total liabilities	3,882,126	2,460,282
Commitments and contingencies (see Note 5)
Stockholders’ equity:
Common stock; $0.001 par value, 180,000,000 shares authorized; 2,519,220 and 2,370,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	2,519	2,370
Additional paid-in capital	129,572,489	128,044,509
Accumulated other comprehensive loss	(203,787)	(148,192)
Accumulated deficit	(124,066,797)	(118,331,653)
Total stockholders’ equity	5,304,424	9,567,034
Total liabilities and stockholders’ equity	$ 9,186,550	$ 12,027,316

About TFF Pharmaceuticals Inc

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.

CEO	Dr. Harlan F. Weisman
WEBSITE	https://tffpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	15

TFF Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for TFF Pharmaceuticals Inc? What does TFFP stand for in stocks?

TFFP is the stock ticker symbol of TFF Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TFF Pharmaceuticals Inc (TFFP)?

As of Fri May 17 2024, market cap of TFF Pharmaceuticals Inc is 6.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TFFP stock?

You can check TFFP's fair value in chart for subscribers.

What is the fair value of TFFP stock?

You can check TFFP's fair value in chart for subscribers. The fair value of TFF Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TFF Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TFFP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TFF Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TFFP is over valued or under valued. Whether TFF Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact TFF Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TFFP.

What is TFF Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TFFP's PE ratio (Price to Earnings) is -0.34 and Price to Sales (PS) ratio is 7.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TFFP PE ratio will change depending on the future growth rate expectations of investors.